ArticleAmerican journal of physiology. Lung cellular and molecular physiology2011
S-nitrosoglutathione supplementation to ovalbumin-sensitized and -challenged mice ameliorates methacholine-induced bronchoconstriction.
Article in American journal of physiology. Lung cellular and molecular physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- S-nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis.Free radical biology & medicine · 2018Article
- The polymeric mucin Muc5ac is required for allergic airway hyperreactivity.Nature communications · 2015Article
- Phenotypes, Risk Factors, and Mechanisms of Adult-Onset Asthma.Mediators of inflammation · 2015Review
- Phenotype of asthmatics with increased airway S-nitrosoglutathione reductase activity.The European respiratory journal · 2015Article
- Mesenchymal stromal cells mediate Aspergillus hyphal extract-induced allergic airway inflammation by inhibition of the Th17 signaling pathway.Stem cells translational medicine · 2014Article
- Pharmacologic inhibition of S-nitrosoglutathione reductase protects against experimental asthma in BALB/c mice through attenuation of both bronchoconstriction and inflammation.BMC pulmonary medicine · 2014Article
- Solid-phase capture for the detection and relative quantification of S-nitrosoproteins by mass spectrometry.Methods (San Diego, Calif.) · 2013Review
- S-nitrosoglutathione reductase inhibition regulates allergen-induced lung inflammation and airway hyperreactivity.PloS one · 2013Article
- Sesame oil attenuates ovalbumin-induced pulmonary edema and bronchial neutrophilic inflammation in mice.BioMed research international · 2013Article
- Modulation of Asthma Pathogenesis by Nitric Oxide Pathways and Therapeutic Opportunities.Drug discovery today. Disease mechanisms · 2012Article
- Glutathione redox control of asthma: from molecular mechanisms to therapeutic opportunities.Antioxidants & redox signaling · 2012Review
- Airway Hyperresponsiveness and Inflammation: Causation, Correlation, or No Relation?Journal of allergy & therapy · 2012Article
Corrections and comments
- Retraction · 2015-04-01Concerns/Issues about Data · Concerns/Issues about Image · Falsification/Fabrication of Data · Falsification/Fabrication of Image · Investigation by Company/Institution · Investigation by ORI · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · Results Not Reproducible · · W Michael Foster = William Michael Foster; EN Potts aka EN Potts-Kant aka Erin N Potts-Kant aka Erin Nicole Potts-Kant; Erin Nicole Potts-Kant has ORI finding of misconduct; https://ori.hhs.gov/sites/default/files/2019-11/2019-24291.pdf;
- Commented on by
- Retracted
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
S-nitrosoglutathione (GSNO) is an endogenous bronchodilator present in micromolar concentrations in airway lining fluid. Airway GSNO levels decrease in severe respiratory failure and asthma, which is attributable to increased metabolism by GSNO reductase (GSNOR). Indeed, we have found that GSNOR expression and activity correlate inversely with lung S-nitrosothiol (SNO) content and airway hyperresponsiveness (AHR) to methacholine (MCh) challenge in humans with asthmatic phenotypes (Que LG, Yang Z, Stamler JS, Lugogo NL, Kraft M. Am J Respir Crit Care Med 180: 226-231, 2009). Accordingly, we hypothesized that local aerosol delivery of GSNO could ameliorate AHR and inflammation in the ovalbumin-sensitized and -challenged (OVA) mouse model of allergic asthma. Anesthetized, paralyzed, and tracheotomized 6-wk-old male control and OVA C57BL/6 mice were administered a single 15-s treatment of 0-100 mM GSNO. Five minutes later, airway resistance to MCh was measured and SNOs were quantified in bronchoalveolar lavage (BAL). Duration of protection was evaluated following nose-only exposure to 10 mM GSNO for 10 min followed by measurements of airway resistance, inflammatory cells, and cytokines and chemokines at up to 4 h later. Acute delivery of GSNO aerosol protected OVA mice from MCh-induced AHR, with no benefit seen above 20 mM GSNO. The antibronchoconstrictive effects of GSNO aerosol delivered via nose cone were sustained for at least 4 h. However, administration of GSNO did not alter total BAL cell counts or cell differentials and had modest effects on cytokine and chemokine levels. In conclusion, in the OVA mouse model of allergic asthma, aerosolized GSNO has rapid and sustained antibronchoconstrictive effects but does not substantially alter airway inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.